Antibodies

03 Apr 2017 Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 and DKN-01 at the 2017 AACR Annual Meeting
03 Apr 2017 Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update
03 Apr 2017 XBiotech Announces Top-Line Results for 514G3 Antibody Therapy in Serious Staphylococcus aureus Infections
03 Apr 2017 Sutro ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival in Tumor Models
03 Apr 2017 Aptevo Therapeutics’ Next Generation ADAPTIR™ Bispecific Antibody Candidates Show Potent Immune Activation
03 Apr 2017 Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
03 Apr 2017 Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003
03 Apr 2017 Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma
03 Apr 2017 Five Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at 2017 AACR Annual Meeting
03 Apr 2017 Opthea Reports Positive Phase 1/2A Clinical Results for OPT-302 in wet AMD
03 Apr 2017 Eleven Biotherapeutics Presents New Preclinical Data at AACR Supporting the Potential of the Company’s Locally- and Systematically-Administered Drug Candidates
02 Apr 2017 Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease
02 Apr 2017 Mersana Therapeutics Presents Preclinical Data on XMT-1522 Supporting Efficacy and Tolerability
02 Apr 2017 Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials
01 Apr 2017 Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab)
01 Apr 2017 Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)
30 Mar 2017 Phase II Study of Daratumumab in Non-Hodgkin's Lymphoma Will Not Proceed to Stage 2 of Trial
30 Mar 2017 First-in-Human Genolimzumab Phase 1 Study Initiated to Assess Safety and Preliminary Efficacy in Patients with Select Advanced Solid Tumors
30 Mar 2017 U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information
30 Mar 2017 FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application
30 Mar 2017 FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers
29 Mar 2017 JHL Doses First Patient In JHL1101 Phase I European Trial
29 Mar 2017 FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
28 Mar 2017 Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
28 Mar 2017 Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top